Please login to the form below
Advate
This page shows the latest Advate news and features for those working in and with pharma, biotech and healthcare.
Shire wins FDA approval for haemophilia dosing software
The web-based myPKFiT supports the pharma firm's Advate treatment. US regulators have approved Shire’s new web-based dosing software for its recombinant Factor VIII haemophilia A treatment Advate. ... A version of the myPKFiT for Advate software has
Latest news
-
Shire claims EU approval for haemophilia A drug Adynovi
The European Commission has approved Shire’s haemophilia A therapy Adynovi, a new long-acting version of its long-established Advate product.
-
Shire wins CHMP backing for Adynovi
The injectable is a new form of Advate - a haemophilia A treatment Shire acquired from Baxalta in a $32bn takeover - and offers twice-weekly prophylactic use as well as on-demand
-
Sobi looks to real-world trial to push Elocta take-up
to wrest market share from established haemophilia A therapies such as Shire/Baxalta's Advate (octocog alfa).
-
Baxalta agrees to $32bn Shire takeover
The merger will couple Baxalta's haemophilia franchise - including its big selling Advate product for haemophilia A and long-acting follow-up BAX-855 which is nearing the market- with Shire
-
First von Willebrand disease therapy heads new FDA approvals
Last month it secured FDA approval for long-acting haemophilia A therapy Adynovate (formerly BAX 855), a follow-up to its big-selling Advate brand.
More from news
Approximately 3 fully matching, plus 21 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Senior Account Executive, Medical/ Brand Communications, London
-
Highly competitive salary
-
Senior Health Psychologist, London
-
Highly competitive salary
-
Head of Health Psychology, London
-
Highly competitive salary
-
Consultant Dermatologist (Freelance)
-
£110-180ph
- Scientists discover new approach to treat brain tumours
- Recognising HIV Vaccine Awareness Day
- Boehringer Ingelheim’s pulmonary fibrosis treatment produces promising phase 2 data
- J&J appoints Thibaut Mongon as CEO designate of New Consumer Health Company
- NICE recommends AstraZeneca’s Imfinzi for adults with non-small cell lung cancer
- Phase 3 trial of AstraZeneca and Avillion’s PT027 shows promise for asthma patients
- Live Webinar: The Future of MedTech: Streamlined Clinical Data Collection & Management
- Medscape: Connect to the conversation
- A Medscape 4-part video interview series
- Why big pharma needs to be braver
- MadMicrobe Studios Inc Announces New European Venture
- EMA accepts Valneva’s marketing authorisation application for COVID-19 vaccine
PMHub
Thrive Agency
We are a specialist health communication agency creating powerful and trusted content. If you’re looking for a partner to help...
Latest intelligence
- Why big pharma needs to be braver
- The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
- Leveraging Real-World Evidence for Cell and Gene Therapies
- Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
- Food Allergy – Is avoidance the only option?
- Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...
